Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
A Study to Evaluate Safety, Immunogenicity and Efficacy of GSK Biologicals HPV-16/18 L1/AS04 Vaccine Administered Intramuscularly According to a Three-dose Schedule (0, 1, 6 Month) in Healthy Adult Female Subjects Aged 26 Years and Above
Sponsor: GlaxoSmithKline
Listed as NCT00294047, this PHASE3 trial focuses on Infections, Papillomavirus and Papillomavirus Vaccines and remains completed. Sponsored by GlaxoSmithKline, it has been updated 9 times since 2006, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Sep 2018 — Feb 2020 [monthly]
Completed PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Feb 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aberdeen, United Kingdom, Akron, United States, Albuquerque, United States, Almada, Portugal, Amsterdam, Netherlands, Augusta, United States, Aurora, United States, Austin, United States, Bangkok, Thailand, Bardstown, United States and 56 more location s